



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

IAG933

Cat. No.:	HY-158384
Molecular Formula:	C ₂₇ H ₂₆ ClF ₂ N ₃ O ₄
Molecular Weight:	529.96
Target:	YAP
Pathway:	Stem Cell/Wnt
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	<p>IAG933 is a small molecule compound. IAG933 is a direct and selective disruptor of YAP-TEAD protein-protein interaction (PPI). By binding to the Ω-loop pocket of TEAD protein, IAG933 directly prevents YAP/TAZ from forming complexes with TEADs, thereby interfering with YAP's carcinogenic function. IAG933 can be used to study the Hippo signaling pathway and specific types of cancer^[1].</p>								
In Vitro	<p>IAG933 (0.0001-10 μM, 24 h) almost completely inhibits the expression of direct TEAD target genes CCN1, ANKRD1 and CCN2 in both MSTO-211H cells and another Hippo-altered mesothelioma line NCI-H226, with IC₅₀ values between 11 and 26 nM. Particularly in mesothelioma, IAG933 shows half-maximal growth inhibition (GI₅₀) values between 13 and 91 nM irrespective of pathway alterations^[1].</p> <p>IAG933 (0.0001-10 μM, 72 h) shows significant anti-proliferative activity in tumor cell lines with multiple Hippo signaling pathway alterations, especially in pleural mesothelioma cell lines^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Proliferation Assay^[1]</p> <table border="1" data-bbox="342 1297 1515 1598"> <tr> <td>Cell Line:</td> <td>TEAD-dependent mesothelioma lines</td> </tr> <tr> <td>Concentration:</td> <td>0.37 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>72 h</td> </tr> <tr> <td>Result:</td> <td>Showed significant anti-proliferative activity in mesothelioma, hippo altered, and non-hippo mutant cell lines, and the cell line activity decreased to less than 10% after 72 hours of administration</td> </tr> </table>	Cell Line:	TEAD-dependent mesothelioma lines	Concentration:	0.37 μM	Incubation Time:	72 h	Result:	Showed significant anti-proliferative activity in mesothelioma, hippo altered, and non-hippo mutant cell lines, and the cell line activity decreased to less than 10% after 72 hours of administration
Cell Line:	TEAD-dependent mesothelioma lines								
Concentration:	0.37 μM								
Incubation Time:	72 h								
Result:	Showed significant anti-proliferative activity in mesothelioma, hippo altered, and non-hippo mutant cell lines, and the cell line activity decreased to less than 10% after 72 hours of administration								
In Vivo	<p>IAG933 (30-240 mg/kg, op.; 24 h) shows rapid and efficient inhibition of TEAD transcription in mouse MSTO-211H cell-derived xenograft (CDX) models in a single dose evaluation experiment^[1].</p> <p>IAG933 (70 and 210 mg/kg, op.; 28 days) prevents mouse morbidity induced by increasing tumor burden in pleura, and antitumor responses are sustained over 4 weeks. IAG933 does not cause weight loss or tolerance problems in mouse models^[1].</p> <p>IAG933 (10 and 30 mg/kg, op.; 14 days) is well tolerated in a rat model where the degree of tumor exposures is proportional to dose and no weight loss was observed^[1].</p> <p>IAG933 (200 mg/kg, op.; 70 days) shows an antitumor response in an NF2-altered PDX model of triple-negative breast cancer^[1].</p>								

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NF2-altered PDX model of triple-negative breast cancer ^[1]
Dosage:	200 mg/kg
Administration:	Oral gavage (p.o.)
Result:	Demonstrated a favorable tumor response, including deep tumor shrinkage and persistent tumor arrest.

Animal Model:	mouse MSTO-211H cell-derived xenograft (CDX) models ^[1]
Dosage:	30-240 mg/kg
Administration:	Oral gavage (p.o.)
Result:	Demonstrated dose-dependent antitumor effects, including tumor arrest and significant tumor shrinkage. At a dose of 240 mg/kg, nearly complete regression of the tumor was observed. No weight loss was observed during treatment.

REFERENCES

[1]. Chapeau EA, et al. Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers. Nat Cancer. 2024 Apr 2.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA